HIV vaccine, Vaccination, HIV/AIDS, Immune system, Infectious disease, AIDS
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
Today, we announced our collaboration with Gritstone to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a potentially curative treatment for HIV infection: https://t.co/yaCEyiWXjI https://t.co/OwtxHnuwLS
OpenGilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
Today, we announced our collaboration with Gritstone to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a potentially curative treatment for HIV infection: https://t.co/yaCEyiWXjI https://t.co/OwtxHnuwLS
OpenGilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
We are sorry, we could not find the related article
If you are curious about Biotech Essentials, the Influencers Review and Career and Jobs
Please click on:
Or signup to our newsletters
Other Essentials
AI Essentials
Robotics
Robotics
Ethics
Ethics
Research
Research
Applied Use Cases
Applied Use Cases
Marketing
Marketing
Healthcare
Healthcare
Cybersecurity
Cybersecurity
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
FOSTER CITY, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company ...
Johnson & Johnson Announces New Public-Private Partnership to Support First Phase 3 Efficacy Study of Janssen’s Investigational Prophylactic HIV Vaccine
National Institutes of Health (NIH), HIV Vaccine Trials Network (HVTN) and U.S. Army Medical Research and Development Command (USAMRDC) join forces with Johnson & Johnson to advance global ...
Moderna Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
Phase 2 study expected to enroll 600 participants Finalizing protocol for Phase 3 study, expected to begin in July 2020 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 29, 2020-- Moderna, Inc. , ...
GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update
The Underlying Value of GeoVax, and the Promise of the Technology...A Comprehensive Review of GeoVax's Various Development Programs ATLANTA, GA, November 7, 2019 – GeoVax Labs, Inc. (OTCQB: ...
Lessons from AIDS for the COVID-19 Pandemic
We can learn from parallels between the coronavirus and HIV crises
HIV prevention is making progress. And a breakthrough vaccine appears within reach
A spate of large-scale clinical trials has scientists hopeful about a vaccine to prevent HIV.
HIV vaccine in 2021? Leading experts 'optimistic' about ongoing trials
Drs. Susan Buchbinder and Anthony Fauci, two of the world’s leading HIV experts, say three ongoing HIV vaccine trials are reason to be hopeful.
Scholar Rock Appoints Tony Kingsley as President and CEO
- Nagesh Mahanthappa , Ph.D., MBA, company’s founding chief executive, passes the baton after leading company since 2012 - Tony Kingsley , a proven leader with a successful track record of ...
Could certain COVID-19 vaccines leave people more vulnerable to the AIDS virus?
Cold-causing adenovirus used in four experimental COVID-19 vaccines increased risk of HIV infection when used in AIDS vaccine trials